Sugi Predict

Sugi Predict / Compounds / SCHEMBL1102262

SCHEMBL1102262

SCHEMBL1102262

O=C(CSc1nnc2c(n1)[nH]c1ccccc12)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.79
▸ KMT2A Q03164 2/20 0.79
▸ MAPT P10636 11/20 0.66
▸ POLB P06746 6/20 0.66
▸ TP53 P04637 1/20 0.61
▸ ALDH1A1 P00352 6/20 0.61
▸ FGB P02675 1/20 0.60
▸ TDP1 Q9NUW8 2/20 0.58
▸ RECQL P46063 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ PKM P14618 2/20 0.56
▸ LMNA P02545 4/20 0.56
▸ GAA P10253 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ HPGD P15428 1/20 0.55
▸ HCRTR1 O43613 1/20 0.54
▸ USP2 O75604 1/20 0.54
▸ PPARG P37231 1/20 0.54
▸ HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102096 0.84 MEN1 (0.82) MEN1KMT2AMAPTPOLBTP53
SCHEMBL17444745 0.81 BACE1 (0.66) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL1102052 0.81 SMN1; SMN2 (0.62) MEN1KMT2AMAPTPOLBTP53
SCHEMBL1105446 0.81 ALDH1A1 (0.54) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL1102111 0.80 MAPT (0.63) MEN1KMT2AMAPTPOLBTP53
SCHEMBL1102055 0.80 ALDH1A1 (0.64) MEN1KMT2AMAPTPOLBTP53
SCHEMBL12224733 0.79 MAPT (0.80) MEN1KMT2AMAPTPOLBTP53
SCHEMBL1102099 0.79 PKM (0.57) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL1102018 0.79 TOP2A (0.56) MEN1KMT2AMAPTPOLBTP53
SCHEMBL15113224 0.78 ALDH1A1 (0.84) MEN1KMT2AMAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962244-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2015-02-24 — — US disclosed
US-8962244-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2015-02-24 — — US disclosed
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2013-08-22 — — US disclosed
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2013-08-22 — — US disclosed
US-8377639-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2013-02-19 — — US disclosed
US-8377639-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2013-02-19 — — US disclosed
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 — — US disclosed
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-03-17 — — US disclosed
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-03-17 — — US disclosed
WO-2010151797-A2 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2010-12-29 — — WO disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 — — US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 — — US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 — — US disclosed
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-02-02 — — US disclosed
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 MEN1 1444/4885KMT2A 3013/4885MAPT 4038/4885
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 MEN1 2329/4885KMT2A 3111/4885MAPT 1883/4885
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels SCNN1G, KCNN3, KCNN2 MEN1 2329/4885KMT2A 3111/4885MAPT 1883/4885
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 MEN1 1444/4885KMT2A 3013/4885MAPT 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.